AbbVie Says It Will Present New Data Supporting Leading Gastroenterology Portfolio At 2024 Digestive Disease Week; Company To Present 15 Abstracts, Including Three Oral Presentations, In Crohn's Disease And Ulcerative Colitis
AbbVie Says It Will Present New Data Supporting Leading Gastroenterology Portfolio At 2024 Digestive Disease Week; Company To Present 15 Abstracts, Including Three Oral Presentations, In Crohn's Disease And Ulcerative Colitis
The 2024 Digestive Disease Week (DDW) Annual Meeting will be held on May 18-21 in Washington, D.C., and virtually.
2024年消化系统疾病周（DDW）年会将于5月18日至21日在华盛顿特区以虚拟方式举行。
Data to be presented from the SEQUENCE head-to-head trial comparing risankizumab (SKYRIZI) versus ustekinumab (STELARA) in Crohn's disease include an economic analysis and oral presentation that assessed inflammation biomarkers
- Additional presentations include efficacy and safety data evaluating clinical, endoscopic, and histologic outcomes from both the INSPIRE Phase 3 induction study and the COMMAND Phase 3 maintenance study of risankizumab as a therapy for adults with moderately to severely active ulcerative colitis
在克罗恩病中，SEQUENCE 正面交锋试验中将提供的数据包括经济分析和评估炎症生物标志物的口头陈述
-其他演示包括评估INSPIRE三期诱导研究和COMMAND三期维持研究的临床、内窥镜和组织学结果的疗效和安全性数据，该研究将利桑珠单抗作为成人中度至重度活动性溃疡性结肠炎的疗法